Mustang Bio and uBriGene withdraw and re-file CFIUS notice; new 45-day review period begins Feb 13

MUSTANG BIO, INC.

On Feb 12, 2024, CFIUS granted request to withdraw and re-file the joint voluntary notice for the transaction.
New 45-day review period started Feb 13, 2024, concluding no later than March 28, 2024.
If CFIUS does not conclude by March 28, the proceeding will transition to a second 45-day investigation phase.
The CFIUS review relates to Mustang's sale of its Worcester cell processing facility and associated assets to uBriGene.
CFIUS clearance was not a condition to closing the transaction, but is being pursued voluntarily.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.